Alexion Pharmaceuticals said this week in a securities filing that it is being investigated by the Department of Justice concerning potential violations of the Foreign Corrupt Practices Act.

In a Nov. 2 Form 10-Q filing with the Securities and Exchange Commission, Alexion said it received a request from the Justice Department in October “for the voluntary production of documents and other information pertaining to Alexion’s compliance with the FCPA.”

As previously disclosed, Alexion said it received a subpoena in May in connection with an investigation by the SEC’s Enforcement Division “requesting information related to our grant-making activities and compliance with the FCPA in various countries. The SEC also seeks information related to Alexion’s recalls of specific lots of Soliris and related securities disclosures.”

Alexion said it is cooperating with these investigations.

“At this time, Alexion is unable to predict the duration, scope or outcome of these investigations,” the company stated. “Given the ongoing nature of these investigations, management does not currently believe a loss related to these matters is probable or that the potential magnitude of such loss or range of loss, if any, can be reasonably estimated.”